Skip to main content

Advertisement

SpringerLink
Log in

NRI AT 20: IMMUNO-ONCOLOGY

Checkpoint blockade: the end of the beginning

  • Journal Club
  • Published:

From Nature Reviews Immunology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original articles

  • Leach, D. R. et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 217, 1734–1736 (1996)

    Article  Google Scholar 

  • Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003)

    Article  CAS  Google Scholar 

  • Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712–4717 (2003)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Jedd D. Wolchok

Authors
  1. Jedd D. Wolchok
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jedd D. Wolchok.

Ethics declarations

Competing interests

J.D.W. is a consultant for Amgen, Apricity, Ascentage Pharma, Arsenal IO, Astellas, AstraZeneca, Bayer, Bicara Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Dragonfly, Eli Lilly, F Star, Georgiamune, Idera, Imvaq, Kyowa Hakko Kirin, Maverick Therapeutics, Merck, Neon Therapeutics, Psioxus, Recepta, Tizona, Trieza, Truvax, Trishula, Sellas, Surface Oncology, Syndax, Syntalogic and Werewolf Therapeutics. J.D.W. receives grant/research support from Bristol Myers Squibb and Sephora. J.D.W. has equity in Tizona Pharmaceuticals, Adaptive Biotechnologies, Ascentage, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO, Georgiamune, Trieza and Maverick.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wolchok, J.D. Checkpoint blockade: the end of the beginning. Nat Rev Immunol 21, 621 (2021). https://doi.org/10.1038/s41577-021-00617-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41577-021-00617-9

  • Springer Nature Limited

This article is cited by

Search

Navigation